Does change in cannabis use in established psychosis affect clinical outcome?

Schizophrenia Bulletin

Volumn 39, Issue 2, 2013, Pages 339-348

  Barrowclough, Christine ^a   Emsley, Richard ^a   Eisner, Emily ^a   Beardmore, Ruth ^a   Wykes, Til ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

cannabis; dual diagnosis; positive symptoms; psychosis; schizophrenia; substance use

Indexed keywords

CANNABIS;

ADULT; ARTICLE; COMPARATIVE STUDY; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; POSITIVE SYNDROME; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOSIS; SOCIAL PSYCHOLOGY; SUBSTANCE ABUSE; TREATMENT OUTCOME;

ADULT; CANNABINOID RECEPTOR AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HOSPITALIZATION; HUMANS; MALE; MARIJUANA ABUSE; MARIJUANA SMOKING; MIDDLE AGED; PROSPECTIVE STUDIES; PSYCHOTIC DISORDERS; SUBSTANCE-RELATED DISORDERS; TETRAHYDROCANNABINOL;

EID: 84874550088     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbr152     Document Type: Article

References (34)

1. Koskinen J, Lohonen J, Koponen H, Isohanni M, Miettunen J. Rate of cannabis use disorders in clinical samples of patients with schizophrenia: a meta-analysis. Schizophr Bull. 2009;36:1115-1130.
2. Moore THM, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of psychotic or affective mental heath outcomes: a systematic review. Lancet. 2007;370:319-328. (Pubitemid 47094993)
3. Compton MT, Ramsay CE. The impact of pre-onset cannabis use on age at onset of prodromal and psychotic symptoms. Prim Psychiatr. 2009;16:35-43.
4. Large M, Sharma S, Compton MT, Slade T, Nielssen O. Cannabis use and earlier onset of psychosis: a systematic metaanalysis. Arch Gen Psychiatry. 2011;68:555-561. First published on February 7, 2011. doi:10.1001/ archgenpsychiatry.2011.5
5. Van Os J, Bak M, Hanssen M, Bijl R, de Graaf R, Verdoux H. Cannabis use and psychosis: a longitudinal populationbased study. Am J Epidemiol. 2002;156:319-327. (Pubitemid 34857999)
6. Zammit S, Moore THM, Lingford-Hughes A, et al. Effects of cannabis use on outcomes of psychotic disorders: systematic review. Br J Psychiatry. 2008;193:357-363.
7. Caspari D. Cannabis and schizophrenia: results of a followup study. Eur Arch Psychiatry Clin Neurosci. 1999;249:45-49. (Pubitemid 29366776)
8. Arias Horcajadas F, Sanchez Romero SS, Padin Calo J. Relevance of drug use in clinical manifestations of schizophrenia [Spanish]. Actas Esp Psiquiatr. 2002;30:65-73.
9. Hides L, Dawe S, Kavanaugh DJ, Young RM. Psychotic symptom and cannabis relapse in recent-onset psychosis: prospective study. Br J Psychiatry. 2006;189:137-143. (Pubitemid 44231272)
10. Wade D, Harrigan S, Edwards J, Burgess PM, Whelan G, McGorry PD. Substance misuse in first-episode psychosis: 15-month prospective follow-up study. Br J Psychiatry. 2006;189:229-234. (Pubitemid 44343467)
11. Martinez-Arevalo MJ, Calcedo-Ordonez A, Varo-Prieto JR. Cannabis consumption as a prognostic factor in schizophrenia. Br J Psychiatry. 1994;164:679-681. (Pubitemid 24161269)
12. Grech A, Van Os J, Jones PB, Lewis SW, Murray RM. Cannabis use and outcome of recent onset psychosis. Eur Psychiatry. 2005;20:349-353. (Pubitemid 40978562)
13. Degenhardt L, Tennant C, Gilmour S, et al. The temporal dynamics of relationships between cannabis, psychosis and depression among young adults with psychotic disorders: findings from a 10-month prospective study. Psychol Med. 2007;37:927-934. (Pubitemid 46993593)
14. Foti DJ, Kotov R, Guey LT, Bromet EJ. Cannabis use and the course of schizophrenia: 10-year follow-up after first hospitalization. Am J Psychiatry. 2009;167:987-993.
15. Stirling J, Lewis S, Hopkins R, White C. Cannabis use prior to first onset psychosis predicts spared neurocognition at 10-year follow-up. Schizophr Res. 2005;75:135-137. (Pubitemid 40487981)
16. Swartz MS, Wagner HR, Swanson JW, et al. Substance use and psychosocial functioning in schizophrenia among new enrollees in the NIMH CATIE study. Psychiatr Serv. 2006;57:1110-1116. (Pubitemid 44204903)
17. Barrowclough C, Haddock G, Wykes T, et al. Integrated motivational interviewing and cognitive behavioural therapy for people with psychosis and comorbid substance misuse: randomised controlled trial. BMJ. 2010;341:c6325.
18. Tait L, Birchwood M, Trower P. A new scale (SES) to measure engagement with community mental health services. J Ment Health. 2002;11:191-198. (Pubitemid 34496793)
19. Hogan TP, Awad AG, Eastwood R. A self report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med. 1983;13:177-183. (Pubitemid 13132147)
20. Sobell LC, Sobell MB. Timeline follow-back: a technique for assessing self-reported alcohol consumption. In: Litten R, Allen J, eds. Measuring Alcohol Consumption: Psychosocial and Biochemical Methods. Totowa, NJ: Humana Press; 1992:41-72.
21. Carey KB. Reliability and validity of the time-line followback interview among psychiatric outpatients: a preliminary report. Psychol Addict Behav. 1997;11:26-33. (Pubitemid 27167924)
22. Carey KB, CareyMP,Maisto SA, Henson JM. Temporal stability of the timeline followback interview for alcohol and drug use with psychiatric outpatients. J Stud Alcohol. 2004;65:774-781. (Pubitemid 40096941)
23. Stasiewicz PR, Vincent PC, Bradizza CM, Connors GJ, Maisto SA, Mercer ND. Factors affecting agreement between severely mentally ill alcohol abusers' and collaterals' reports of alcohol and other substance abuse. Psychol Addict Behav. 2008;22:78-87. (Pubitemid 351389760)
24. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276. (Pubitemid 18039085)
25. American Psychiatric Association.Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), 4th Edition.Washington, DC: American Psychiatric Association; 1994.
26. StataCorp.Intercooled Stata Statistical Software: Release 11.1 College Station, TX: Stata Corporation; 2010.
27. Zeger SL, Liang KY. Longitudinal data-analysis for discrete and continuous outcomes. Biometrics. 1986;42:121-130.
28. Twisk J. Applied Longitudinal Data Analysis for Epidemiology: A Practical Guide. Cambridge, UK: Cambridge University Press; 2003.
29. Miles H, Johnson S, Amponsah-Afuwape S, Leese M, Finch E, Thornicroft G. Characteristics of subgroups of individuals with psychotic illness and a comorbid substance use disorder. Psychiatr Serv. 2003;54:554-561. (Pubitemid 36752988)
30. Kavanagh DJ, Waghorn G, Jenner L, et al. Demographic and clinical correlates of comorbid substance use disorders in psychosis: multivariate analyses from an epidemiological sample. Schizophr Res. 2004;66:115-124. (Pubitemid 38041109)
31. ComptonMT, Broussard B, Ramsay CE, Stewart T. Pre-illness cannabis use and the early course of nonaffective psychotic disorders: associations with premorbid functioning, the prodrome, and mode of onset of psychosis. Schizophr Res. 2010;126:71-76.
32. Potter DJ, Clark P, Brown MB. Potency of D-9-THC and other cannabinoids in cannabis in England in 2005: implications for psychoactivity and pharmacology. JForensic Sci. 2008;53:90-94. (Pubitemid 351239216)
33. Hall W, Degenhardt L. Adverse health effects of non-medical cannabis use. Lancet. 2009;374:1383-1391.
34. Richardson TH. Cannabis use and mental health: a review of recent epidemiological research. Int J Pharmacol. 2010;6:796-807.